摘要目的：探讨泛神经标志物蛋白基因产物（PGP）9.5在乳腺癌组织中的表达及其临床病理意义。方法收集2007至2011年乳腺石蜡包埋组织196例，其中正常乳腺组织20例，纤维腺瘤14例，导管内癌18例和浸润性导管癌（ IDC）144例，采用免疫组织化学EnVision 法检测各组织中PGP9.5的表达，并分析其与IDC临床病理特征之间的关系。结果在所有正常乳腺间质中均可见PGP9.5的表达，而在纤维腺瘤和导管内癌组织中未见其表达。在IDC组织中PGP9.5的阳性表达率为61.8％（89/144）。在2、3级IDC组织中PGP9.5的表达水平（71.8％，79/110）高于其在1级中的表达（29.4％，10/34；P＝0.000）。 PGP9.5在无病生存期＜3年患者中的表达水平（64.8％，35/54）高于≥3年的患者（46.7％，42/90；P＝0.035）。 PGP9.5的阳性表达与肿瘤大小、临床分期、淋巴结转移情况、激素受体表达均无相关性。结论 PGP9.5的表达与乳腺IDC的肿瘤分级和预后有关。

abstractsObjective To detect the expression of pan-neuronal marker protein gene product ( PGP)9.5 and its clinicopathologic significance in breast cancer .Methods The expression of PGP9.5 was examined by immunohistochemistry EnVision method in 196 cases during 2007 to 2011, including 20 normal tissues, 14 cases of fibroadenoma , 18 cases of ductal carcinoma in situ ( DCIS) and 144 cases of invasive ductal carcinoma (IDC) of the breast.The relationship between PGP9.5 expression and clinicopathologic characteristics of IDC was assessed.Results PGP9.5 expression was localized in the stroma of all normal breast tissues, but there was no expression observed in all fibroadenomas and DCIS.Overall, the expression rate of PGP9.5 in IDC was 61.8%(89/144).PGP9.5 expression increased from grade 1 tumors (29.4%, 10/34) to grade 2-3 tumors (71.8%, 79/110; P=0.000).In addition, patients with less than 3 years disease-free survival tended to show higher PGP9.5 expression (64.8%, 35/54), compared to patients with equal to and/or more than 3 years disease-free survival (46.7%, 42/90;P=0.035).However, there was no correlation between PGP 9.5 expression and tumor size , tumor stage , lymph metastasis , hormone receptor expression.Conclusion PGP9.5 expression is correlated with tumor grade and prognosis in IDC of the breast.